Sleep ApneaPhase 4ADIPOSANCT05612594
Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study
A Phase 4 study testing Bexagliflozin 20 mg in people with Sleep Apnea, run by Yale University at 2 sites in United States.
Trial summary
The goal of this clinical trial is to test if bexagliflozin lowers the sleep apnea severity in adults who are overweight or obese with moderate to severe obstructive sleep apnea (OSA) compared with a placebo (look-alike substance that contains no active drug). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Sleep Apnea
- What is being tested?
- Bexagliflozin 20 mg
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 164 participants
- Where
- 2 sitesUnited States
- Study dates
- 27 Mar 2024to Sep 2027
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Able to provide informed consent and stated willingness to comply with all study procedures and availability for the duration of the study
- Overweight or obese (body mass index 25-40 kg/m2)
- Clinically confirmed diagnosis of obstructive sleep apnea by one of the following methods:
- Polysomnography: AHI ≥15/hour sleep or b. Home sleep apnea testing: Respiratory event index (REI) ≥15/hour sleep
- AHI: apnea-hypopnea index (apneas + hypopneas / total sleep time in hours)
Who cannot join
- An individual who meets any of the following criteria will be excluded from participation in this study:
- Known non-OSA related conditions associated with sleep disordered breathing (e.g., central disorder of hypersomnolence, neurological, neuromuscular, or pulmonary disorder)
- Use of sleep-inducing medications (e.g. benzodiazepines, opiates, barbiturates)
- Type 1 diabetes mellitus
- History of diabetic ketoacidosis
- Known hypersensitivity reaction to bexagliflozin or any of its constituents or any contraindication to bexagliflozin use
Show all 20Show fewer
- Severe, recurrent urinary tract or genital mycotic infections
- eGFR<30mL/min/1.73m2 at time of or within 4 weeks of enrollment in the study
- Unable to complete/tolerate magnetic resonance imaging (MRI) due to severe claustrophobia or metallic implants.
- Language barrier, mental incapacity, unwillingness or inability to understand.
- Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant.
- Currently or planning to take a SGLT2i prior to or during enrollment in the study
- Currently or planning to follow a ketogenic diet pattern ("keto diet) prior to or during enrollment in the study
- Currently or planning to follow an active weight loss program (including but not limited to use of supplements, medications, or surgery) prior to or during enrollment in the study
- Currently or planning to follow an intermittent fasting diet plan prior to or during enrollment in the study
- Currently or planning to take a GLP-1 receptor agonist prior to or during enrollment in the study .
- Existing lower limb ulcer (due to diabetes or any cause)
- Existing severe peripheral arterial disease with intermittent claudication and/or prior lower limb revascularization procedure
- Concomitant administration of UGT inducers
- Severe liver disease
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States2 sites, 2 recruiting
- Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106
- Recruiting
Yale New Haven Health
New Haven, Connecticut, 06520
About this study
Official title: Adipose Dysfunction, Imaging, Physiology, and Outcomes With SGLT2i's for Sleep Apnea: The ADIPOSA Study
The goal of this clinical trial is to test if bexagliflozin lowers the sleep apnea severity in adults who are overweight or obese with moderate to severe obstructive sleep apnea (OSA) compared with a placebo (look-alike substance that contains no active drug).
The main question it aims to answer is:
Read more
- If SGLT2i will reduce anatomic and physiologic traits, clinical measures of OSA and sleep deficiency in participants
- If improvement in clinical measures are because of improvement in the anatomic and physiologic traits.
Participants will be placed on either drug or placebo and get routine normal care for 6 months. At the start and end of the study, participants will undergo different clinical measurements to see if the drug makes the sleep apnea better.
Read the detailed description
The primary objective of this study is to determine whether bexagliflozin 20 mg once daily compared with placebo reduces the apnea hypopnea index (AHI) in adults with overweight or obesity with moderate to severe OSA.
The secondary objectives of this study are to determine whether bexagliflozin 20 mg once daily compared with placebo (a look-alike substance that contains no active drug):
- reduces visceral and neck fat and upper airway soft tissue structure volumes and increases airway caliber
- reduces Critical closing pressure
- reduces rostral to caudal fluid shifts (measured by neck circumference)
- improves clinical measures of OSA severity and sleep deficiency
This is a 2-center clinical trial of overweight or obese adults (BMI 25-40 kg/m2) diagnosed with moderate to severe OSA, recruited from University Hospitals Cleveland Medical Center (UH) and Yale New Haven Health (YNHH). Participants will be randomized to bexagliflozin 20 mg once daily or matching placebo in addition to standard routine clinical care for both groups for 6 months. At baseline and at study end, participants will undergo measurements of anatomic traits using MRI imaging, critical closing pressure, blood-based biomarkers of dysfunctional adiposity, non-anatomic physiologic trait polysomnographic phenotyping, morning neck circumference, clinical measures of sleep apnea severity (apnea hypopnea index (AHI), oxygen desaturation index (ODI), % time with O2sat < 90% (T90)), sleep arousal index (AI)), and measures of sleep deficiency, to evaluate the effects of SGLT2i on the measured phenotypes.
- Conditions
- Sleep Apnea
- Being tested
- Bexagliflozin 20 mg, Placebo
- Medical subject headings
- Sleep Apnea Syndromes
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Bexagliflozin 20 mgDrug
15mg once daily
PlaceboDrug
matching placebo once daily
| Study group | Role | What they receive |
|---|---|---|
| Bexagliflozin | Experimental | Bexagliflozin once daily for 6 months Receives: Drug: Bexagliflozin 20 mg |
| Placebo | Placebo comparator | Placebo once daily for 6 months Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Apnea hypopnea index (AHI) measured by full ambulatory polysomnography (aPSG)
All participants will undergo a full in-home aPSG with a Nox-A1 system, which collects sleep EEG required to determine the physiologic traits and measures of sleep apnea. This is an unattended sleep monitor. The AHI is the number of apneas or hypopneas recorded during the sleep study per hour of sleep. Higher AHI indicates the severity of sleep apnea.
Measured: Baseline and 6 months
Secondary outcomes (27)
Change in Neck and body fat and lean volume by MRI
Participants will undergo standard measurements including height, weight, waist circumference, hip circumference, and neck circumference by MRI to quantify fat and lean tissue composition in the neck and body. Volumetric imaging datasets of the body will be derived by MRI using validated and readily available protocols with rapid scan time to perform precise measurements of total and regional body composition to quantify fat and lean tissue composition in the neck and body. MRI imaging using a 6-minute dual-echo Dixon Vibe protocol, providing water and fat separated volumetric data set covering neck to knees, and a single-slice multi-echo Dixon acquisition for proton density fat fraction (PDFF) assessment in the liver.
Measured: Baseline and 6 months
Change in Airway caliber by MRI
Volumetric imaging datasets of the body derived by MRI using validated and readily available protocols with rapid scan time to perform precise measurements of total and regional body composition to quantify fat and lean tissue composition in the neck and body, including MRI imaging using a 6-minute dual-echo Dixon Vibe protocol, providing water and fat separated volumetric data set covering neck to knees, and a single-slice multi-echo Dixon acquisition for proton density fat fraction (PDFF) assessment in the liver.
Measured: Baseline and 6 months
Change in Critical closing pressure (Pcrit)/normal ventilatory drive (Vpass) by aPSG
Mathematical modeling to determine the patient's ventilatory drive in response to changes in ventilation induced by upper airway obstruction (i.e., apnea/hypopnea). Pharyngeal collapsibility, calculated as the level of ventilation during sleep at normal or eupneic ventilatory drive (Vpassive) and is a valid proxy for critical closing pressure (Pcrit) and a reflection of the impact of the anatomic traits of sleep apnea.
Measured: Baseline and 6 months
Change in neck circumference
Change in neck circumference measured by tape measure. Measuring the change in the evening to morning neck circumference which is a validated measure of caudal to rostral fluid shift. Higher neck circumference indicates an increase in probability of sleep apnea.
Measured: Baseline and 6 months
Change in Oxygen desaturation index (ODI) measured by aPSG
Percent of time with O2 saturation < 90% (T90) recorded during the aPSG
Measured: Baseline and 6 months
Change in Sleep arousal index (ArI) measured by aPSG
Total arousal index (ArI) was defined as the total number of arousals recorded during the aPSG per hour of sleep.
Measured: Baseline and 6 months
Change in Insomnia Severity Index (ISI)
The Insomnia Severity Index has seven questions. The seven answers are added up to get a total score. Total scores scale:
0-7 = No clinically significant insomnia 8-14 = Subthreshold insomnia 15-21 = Clinical insomnia (moderate severity) 22-28 = Clinical insomnia (severe)
Measured: Baseline, 3 months and 6 months
Change in Sleep Quality measured by Pittsburgh Sleep Quality Index Form
This questionnaire contains 19 self-rated questions that are combined to form seven "component" scores, each of which has a range of 0-3 points. In all cases, a score of 0 indicates no difficulty in that area, while a score of 3 indicates severe difficulty. The seven component scores are then added to yield one global score, with a range of 0-21 points, with 0 indicating no difficulty and 21 indicating severe difficulties in all areas.
The seven component domains are: 1. Subjective sleep quality, 2. Sleep latency, 3. Sleep duration, 4. Habitual sleep efficiency, 5. Step disturbances, 6. Use of sleeping medication, and 7. Daytime dysfunction.
Measured: Baseline, 3 months and 6 months
Change in Reduced Morningness Eveningness Questionnaire (MEQ)
The 5 questions reduced MEQ is a self-assessment questionnaire. Responses to the questions are combined to form a composite score that indicates the degree to which the respondent favors morning versus evening. In Total Score (0-25) higher scores indicate morningness, lower scores indicate eveningness.
Measured: Baseline, 3 months and 6 months
Change in Regulatory Satisfaction Alertness Timing Efficiency Duration (RU-SATED)
Regulatory Satisfaction Alertness Timing Efficiency Duration (RU-SATED) questionnaire. This is a multidimensional metric for sleep health with 6 questions. RU-SATED stands for: regularity of sleep, satisfaction with sleep, alertness during the day, timing of sleep, efficiency of sleep, and duration of sleep. Each question is scored 0, 1, or 2 based on rarely/never, sometimes, usually always responses. The scores are summed, and a higher score indicates better sleep health.
Measured: Baseline, 3 months and 6 months
Change in Sleep Deprivation Questionnaire (SDQ)
The questionnaire is divided into two sections. The first section assesses sleep duration in hours as a weighted average of work night hours and weekend night hours. Sleep deprivation is determined from the reported hours of sleep as follows: ≥7 hours = no sleep deprivation; <7 but ≥5 hours = mild to moderate sleep deprivation; <5 hours = severe sleep deprivation. The second section assesses the circadian timing of sleep by asking questions related to circadian-sleep mismatch; a higher score indicates worse circadian sleep timing.
Measured: Baseline, 3 months and 6 months
Change in STOP - Bang questionnaire
The snoring, tiredness, observed apnea, high BP, BMI, age, neck circumference, and gender (STOP-Bang) questionnaire. The Total Sore 0-8 with higher scores indicating higher risks for obstructive sleep apnea. Affirmative answers get a "1" and the sum of the eight question scores is stratified into low risk for OSA (0-2), moderate risk (3-4), and high risk (5-8).
Measured: Baseline, 3 months and 6 months
Change inThe Sleep Apnea Quality of Life Index (SAQLI).
This is a disease specific quality of life index for OSA in adults. Categories and domains include daily functioning, social interactions, emotional functioning, and symptoms. The scaling of items ranges from "not at all" to "all the time," a seven point scale.
Measured: Baseline, 3 months and 6 months
Change in The Epworth Sleepiness Scale (ESS)
This is a validated scale to assess perceived hypersomnia. Patients are asked to score on a scale of 0 to 3 the likelihood that they would "doze-off" in different scenarios ranging from passes activities to active situations. The low score is zero in the high score is 24. The score of greater than 10 is considered clinically significant hypersomnia.
Measured: Baseline, 3 months and 6 months
Change in height.
Height measured in cm.
Measured: Baseline and 6 months
Change in weight.
Weight will be recorded to the nearest 0.1 kg using calibrated scales. Weight will be measured in a fasting state with an empty bladder, without shoes and only wearing light clothing.
Measured: Baseline and 6 months
Change in body mass index (BMI)
Body mass index (BMI) is a value derived from the mass (weight) and height of a person. The BMI is defined as the body mass divided by the square of the body height, and is expressed in units of kg/m2, resulting from mass in kilograms and height in metres.
Measured: Baseline and 6 months
Change in Waist circumference
Waist circumference measured in cm.
Measured: Baseline and 6 months
Change in hip circumference
Hip circumference measured in cm.
Measured: Baseline and 6 months
Change in sleep walking periods measured using Wrist-wearable actigraphy
The amount of time spent sleep walking in naturalistic settings will be measured using the ActiGraph which will be worn on the non-dominant wrist for 24-hours each day for seven consecutive days.
Measured: Baseline, 3 months and 6 months
Change in 24 hour ambulatory average systolic blood pressure
24-hour ambulatory blood pressure monitoring using a blood pressure monitoring device to measure average systolic blood pressure
Measured: Baseline, 3 months and 6 months
Change in 24 hour ambulatory average diastolic blood pressure
24-hour ambulatory blood pressure monitoring using a blood pressure monitoring device to measure average diastolic blood pressure
Measured: Baseline, 3 months and 6 months
Change in 24 hour ambulatory blood pressure variability
24-hour ambulatory blood pressure monitoring using a blood pressure monitoring device measure blood pressure variability over 24 hour monitoring session.
Measured: Baseline, 3 months and 6 months
Change in 24 hour ambulatory nighttime blood pressure dipping
Comparing average BP during wakefulness to average BP during major sleep episode in 24 hours monitoring session
Measured: Baseline, 3 months and 6 months
Change in Vdrive/Loop gain by aPSG
Mathematical modeling to determine the patient's ventilatory drive (or desired ventilation, Vdrive) in response to changes in ventilation induced by upper airway obstruction (i.e., apnea/hypopnea). The Vdrive signal is fit to the ventilation (VE) signals when the airway is expected to be patent (VE = Vdrive). Recorded during the sleep study. Measures of Vdrive allow determinations of Loop gain (LG), measured by the increase in ventilatory drive that occurs following a unit reduction in ventilation due to apneas/hypopneas.
Measured: Baseline and 6 months
Vdrive/Arousal threshold (ArTH) by aPSG
Mathematical modeling to determine the patient's ventilatory drive (or desired ventilation, Vdrive) in response to changes in ventilation induced by upper airway obstruction (i.e., apnea/hypopnea). The Vdrive signal is fit to the ventilation (VE) signals when the airway is expected to be patent (VE = Vdrive). Recorded during the sleep study. Measures of Vdrive allow determinations of Arousal threshold (ArTH), quantified as the level of "ventilatory drive" just before arousal from sleep.
Measured: Baseline and 6 months
Vdrive/Pharyngeal muscle compensation (Mresp) by aPSG
Mathematical modeling to determine the patient's ventilatory drive (or desired ventilation, Vdrive) in response to changes in ventilation induced by upper airway obstruction (i.e., apnea/hypopnea). The Vdrive signal is fit to the ventilation (VE) signals when the airway is expected to be patent (VE = Vdrive). Recorded during the sleep study. Measures of Vdrive allow determinations of Pharyngeal muscle compensation (Mresp), assessed by the increase in ventilation achieved during sleep per unit increase in the ventilatory drive. The analysis is automated using custom MATLAB software.
Measured: Baseline and 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Nov 2022
- Study start27 Mar 2024
- Primary completionSep 2027 (estimated)
- Study completionSep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sleep ApneaStudies of the same condition, open and under way.
- More trials run by Yale UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 164 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Yale University
- Sponsor type
- University, hospital or other
- Collaborators
- Case Western Reserve University
- Responsible party
- Sponsor
- Investigators
- Henry K Yaggi, M.D., Principal investigator, Yale UniversityIan J Neeland, M.D., Principal investigator, Case Western Reserve University School of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05612594
- Sponsor's protocol ID
- 2000033371
- Acronym
- ADIPOSA
- Status last verified
- Aug 2026
- First submitted
- 3 Nov 2022
- Last updated
- 27 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Adipose Dysfunction, Imaging, Physiology, and Outcomes With SGLT2i's for Sleep Apnea: The ADIPOSA Study
- ClinicalTrials.gov ID
- NCT05612594
- Acronym / sponsor ID
- ADIPOSA / 2000033371
- Conditions
- Sleep Apnea
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 164 participants (estimated)
- Lead sponsor
- Yale UniversityUniversity, hospital or other
- Collaborators
- Case Western Reserve University
- Study start
- 27 Mar 2024 (actual)
- Primary completion
- Sep 2027 (estimated)
- Study completion
- Sep 2027 (estimated)
- First posted
- 10 Nov 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to test if bexagliflozin lowers the sleep apnea severity in adults who are overweight or obese with moderate to severe obstructive sleep apnea (OSA) compared with a placebo (look-alike substance that contains no active drug).
The main question it aims to answer is:
- If SGLT2i will reduce anatomic and physiologic traits, clinical measures of OSA and sleep deficiency in participants
- If improvement in clinical measures are because of improvement in the anatomic and physiologic traits.
Participants will be placed on either drug or placebo and get routine normal care for 6 months. At the start and end of the study, participants will undergo different clinical measurements to see if the drug makes the sleep apnea better.
Detailed description
The primary objective of this study is to determine whether bexagliflozin 20 mg once daily compared with placebo reduces the apnea hypopnea index (AHI) in adults with overweight or obesity with moderate to severe OSA.
The secondary objectives of this study are to determine whether bexagliflozin 20 mg once daily compared with placebo (a look-alike substance that contains no active drug):
- reduces visceral and neck fat and upper airway soft tissue structure volumes and increases airway caliber
- reduces Critical closing pressure
- reduces rostral to caudal fluid shifts (measured by neck circumference)
- improves clinical measures of OSA severity and sleep deficiency
This is a 2-center clinical trial of overweight or obese adults (BMI 25-40 kg/m2) diagnosed with moderate to severe OSA, recruited from University Hospitals Cleveland Medical Center (UH) and Yale New Haven Health (YNHH). Participants will be randomized to bexagliflozin 20 mg once daily or matching placebo in addition to standard routine clinical care for both groups for 6 months. At baseline and at study end, participants will undergo measurements of anatomic traits using MRI imaging, critical closing pressure, blood-based biomarkers of dysfunctional adiposity, non-anatomic physiologic trait polysomnographic phenotyping, morning neck circumference, clinical measures of sleep apnea severity (apnea hypopnea index (AHI), oxygen desaturation index (ODI), % time with O2sat < 90% (T90)), sleep arousal index (AI)), and measures of sleep deficiency, to evaluate the effects of SGLT2i on the measured phenotypes.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Bexagliflozin | Experimental | Drug: Bexagliflozin 20 mgBexagliflozin once daily for 6 months |
| Placebo | Placebo comparator | Drug: PlaceboPlacebo once daily for 6 months |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Able to provide informed consent and stated willingness to comply with all study procedures and availability for the duration of the study
- Overweight or obese (body mass index 25-40 kg/m2)
- Clinically confirmed diagnosis of obstructive sleep apnea by one of the following methods:
- AHI: apnea-hypopnea index (apneas + hypopneas / total sleep time in hours)
Key exclusion criteria (20 listed)
- An individual who meets any of the following criteria will be excluded from participation in this study:
- Known non-OSA related conditions associated with sleep disordered breathing (e.g., central disorder of hypersomnolence, neurological, neuromuscular, or pulmonary disorder)
- Use of sleep-inducing medications (e.g. benzodiazepines, opiates, barbiturates)
- Type 1 diabetes mellitus
- History of diabetic ketoacidosis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Bexagliflozin 20 mg15mg once daily | Drug | Bexagliflozin |
| Placebomatching placebo once daily | Drug | Placebo |
Primary outcome
Change in Apnea hypopnea index (AHI) measured by full ambulatory polysomnography (aPSG)
Time frame: Baseline and 6 months
All participants will undergo a full in-home aPSG with a Nox-A1 system, which collects sleep EEG required to determine the physiologic traits and measures of sleep apnea. This is an unattended sleep monitor. The AHI is the number of apneas or hypopneas recorded during the sleep study per hour of sleep. Higher AHI indicates the severity of sleep apnea.
27 secondary outcomes
Change in Neck and body fat and lean volume by MRI
Time frame: Baseline and 6 months
Change in Airway caliber by MRI
Time frame: Baseline and 6 months
Change in Critical closing pressure (Pcrit)/normal ventilatory drive (Vpass) by aPSG
Time frame: Baseline and 6 months
Change in neck circumference
Time frame: Baseline and 6 months
Change in Oxygen desaturation index (ODI) measured by aPSG
Time frame: Baseline and 6 months
Change in Sleep arousal index (ArI) measured by aPSG
Time frame: Baseline and 6 months
Change in Insomnia Severity Index (ISI)
Time frame: Baseline, 3 months and 6 months
Change in Sleep Quality measured by Pittsburgh Sleep Quality Index Form
Time frame: Baseline, 3 months and 6 months
Change in Reduced Morningness Eveningness Questionnaire (MEQ)
Time frame: Baseline, 3 months and 6 months
Change in Regulatory Satisfaction Alertness Timing Efficiency Duration (RU-SATED)
Time frame: Baseline, 3 months and 6 months
Change in Sleep Deprivation Questionnaire (SDQ)
Time frame: Baseline, 3 months and 6 months
Change in STOP - Bang questionnaire
Time frame: Baseline, 3 months and 6 months
Change inThe Sleep Apnea Quality of Life Index (SAQLI).
Time frame: Baseline, 3 months and 6 months
Change in The Epworth Sleepiness Scale (ESS)
Time frame: Baseline, 3 months and 6 months
Change in height.
Time frame: Baseline and 6 months
Change in weight.
Time frame: Baseline and 6 months
Change in body mass index (BMI)
Time frame: Baseline and 6 months
Change in Waist circumference
Time frame: Baseline and 6 months
Change in hip circumference
Time frame: Baseline and 6 months
Change in sleep walking periods measured using Wrist-wearable actigraphy
Time frame: Baseline, 3 months and 6 months
Change in 24 hour ambulatory average systolic blood pressure
Time frame: Baseline, 3 months and 6 months
Change in 24 hour ambulatory average diastolic blood pressure
Time frame: Baseline, 3 months and 6 months
Change in 24 hour ambulatory blood pressure variability
Time frame: Baseline, 3 months and 6 months
Change in 24 hour ambulatory nighttime blood pressure dipping
Time frame: Baseline, 3 months and 6 months
Change in Vdrive/Loop gain by aPSG
Time frame: Baseline and 6 months
Vdrive/Arousal threshold (ArTH) by aPSG
Time frame: Baseline and 6 months
Vdrive/Pharyngeal muscle compensation (Mresp) by aPSG
Time frame: Baseline and 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Sleep Apnea
RecruitingObservational study
Development of a Wearable Point of Care Monitoring Device for Pediatric Obstructive Sleep Apnea
Pediatric Obstructive Sleep Apnea
RecruitingPhase 1/2
DRonabinol Treatment of OSA
Obstructive Sleep Apnea
RecruitingObservational study
Predictive Factors for Occlusal Changes in Obstructive Sleep Apnea Treatment With Mandibular Advancement Appliance
Obstructive Sleep Apnea Syndrome
RecruitingPhase 3
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)
Apnea, Sleep Disorders
Active, not recruitingPhase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy
Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Henry K Yaggi, M.D. principal investigator
Yale University
Ian J Neeland, M.D. principal investigator
Case Western Reserve University School of Medicine
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Bexagliflozin 20 mg in people with Sleep Apnea, run by Yale University at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 27 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Henry K Yaggi, M.D. (203-785-4163, henry.yaggi@yale.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Apnea hypopnea index (AHI) measured by full ambulatory polysomnography (aPSG) (time frame: Baseline and 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Aug 2026.